Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
3
75%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
N/ANon-phased studies
3(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Completed(1)

Detailed Status

Recruiting2
Enrolling by invitation1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A3 (100.0%)

Trials by Status

enrolling_by_invitation125%
recruiting250%
completed125%

Recent Activity

2 active trials
Showing 4 of 4
enrolling_by_invitationnot_applicable

Tracking and Predicting How Brain Damage Spreads in Neurodegenerative Diseases

NCT07567664
recruitingnot_applicable

Biocollection of Rare Pediatric-onset of Autoimmune and Autoinflammatory Diseases

NCT06435468
recruiting

Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer

NCT04638725
completednot_applicable

The Study of the Prevalence Fibromuscular Dysplasia in Patient With Haematoma or Spontaneous Coronary Artery Dissection.

NCT02799186

Clinical Trials (4)

Showing 4 of 4 trials
NCT07567664Not Applicable

Tracking and Predicting How Brain Damage Spreads in Neurodegenerative Diseases

Enrolling By Invitation
NCT06435468Not Applicable

Biocollection of Rare Pediatric-onset of Autoimmune and Autoinflammatory Diseases

Recruiting
NCT04638725

Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer

Recruiting
NCT02799186Not Applicable

The Study of the Prevalence Fibromuscular Dysplasia in Patient With Haematoma or Spontaneous Coronary Artery Dissection.

Completed

All 4 trials loaded

Drug Details

Intervention Type
GENETIC
Total Trials
4